Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | New Horizons in PNH

Regis Peffault de Latour • 15 Jun 2019
EHA 2019
Non-Malignant Paroxysmal Nocturnal Hemoglobinuria Eculizumab Rovelizumab

Regis Peffault de Latour, MD, PhD, Saint Louis Hospital, Paris, France, discusses up-and-coming therapies for paroxysmal nocturnal hemoglobinuria (PNH). This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Regis Peffault de Latour

2:55
RACE: evaluating eltrombopag in severe aplastic anemia
Regis Peffault de Latour • 3 Sep 2020
1:17
Overview of HSCT and GvHD at EBMT
Regis Peffault de Latour • 3 Sep 2020
2:01
Eltrombopag for aplastic anaemia in Europe
Regis Peffault de Latour • 1 Sep 2020
2:21
LNP023 for paroxysmal nocturnal hemoglobinuria
Regis Peffault de Latour • 2 Sep 2020

Related Videos

2:01
The MDT in the new era of gene therapy for hemoglobinopathies
Mattia Algeri • 15 Apr 2024
2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals